Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis

被引：638

作者：

Pepper, MS ^{[1
]}

机构：

[1] Ctr Med Univ Geneva, Dept Morphol, CH-1211 Geneva 4, Switzerland

来源：

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2001年 / 21卷 / 07期

关键词：

extracellular matrix; endothelium; metalloproteinase; plasminogen; cancer;

D O I：

10.1161/hq0701.093685

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Extracellular proteolysis is an absolute requirement for new blood vessel formation (angiogenesis). This review examines the role of the matrix metalloproteinase (MMP) and plasminogen activator (PA)-plasmin systems during angiogenesis. Specifically, a role for gelatinases (MMP-2, MMP-9), membrane-type 1 MMP (MMP-14), the urokinase-type PA receptor, and PA inhibitor I has been clearly defined in a number of model systems. The MMP and PA-plasmin systems have also been implicated in experimental vascular tumor formation, and their role during this process will be examined. Antiproteolysis, particularly in the context of angiogenesis, has become a key target in therapeutic strategies aimed at inhibiting tumor growth and other diseases associated with neovascularization.

引用

页码：1104 / 1117

页数：14

共 174 条

[1] Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis [J].

Ahrens, D ;

Koch, AE ;

Pope, RM ;

SteinPicarella, M ;

Niedbala, MJ .

ARTHRITIS AND RHEUMATISM, 1996, 39 (09) :1576-1587

[2] The plasminogen activation system in tumor growth, invasion, and metastasis [J].

Andreasen, PA ;

Egelund, R ;

Petersen, HH .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) :25-40

[3] SYNERGISTIC EFFECT OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND BASIC FIBROBLAST GROWTH-FACTOR ON ANGIOGENESIS IN-VIVO [J].

ASAHARA, T ;

BAUTERS, C ;

ZHENG, LP ;

TAKESHITA, S ;

BUNTING, S ;

FERRARA, N ;

SYMES, JF ;

ISNER, JM .

CIRCULATION, 1995, 92 (09) :365-371

[4] Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: A mechanism for balancing pericellular proteolysis during angiogenesis [J].

Bacharach, E ;

Itin, A ;

Keshet, E .

BLOOD, 1998, 92 (03) :939-945

[5] The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies [J].

Bajou, K ;

Masson, V ;

Gerard, RD ;

Schmitt, PM ;

Albert, V ;

Praus, M ;

Lund, LR ;

Frandsen, TL ;

Brunner, N ;

Dano, K ;

Fusenig, NE ;

Weidle, U ;

Carmeliet, G ;

Loskutoff, D ;

Collen, D ;

Carmeliet, P ;

Foidart, JM ;

Noël, AS .

JOURNAL OF CELL BIOLOGY, 2001, 152 (04) :777-784

[6] Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].

Bajou, K ;

Noël, A ;

Gerard, RD ;

Masson, V ;

Brunner, N ;

Holst-Hansen, C ;

Skobe, M ;

Fusenig, NE ;

Carmeliet, P ;

Collen, D ;

Foidart, JM .

NATURE MEDICINE, 1998, 4 (08) :923-928

[7] Thrombospondin type 1 repeats interact with matrix metalloproteinase 2 - Regulation of metalloproteinase activity [J].

Bein, K ;

Simons, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (41) :32167-32173

[8] Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].

Bergers, G ;

Brekken, R ;

McMahon, G ;

Vu, TH ;

Itoh, T ;

Tamaki, K ;

Tanzawa, K ;

Thorpe, P ;

Itohara, S ;

Werb, Z ;

Hanahan, D .

NATURE CELL BIOLOGY, 2000, 2 (10) :737-744

[9]

BERMAN M, 1982, INVEST OPHTH VIS SCI, V22, P191

[10]

Besser D, 1995, ONCOGENE, V11, P2383

← 1 2 3 4 5 6 7 8 9 10 →